Guselkumab efficacy and safety in East Asian participants with moderately to severely active Crohn’s disease: subgroup analysis of the phase 3 GALAXI 2 and GALAXI 3 trials

May 21, 2026Intestinal ResearchOpen Access

View Full Paper

Ask AI

Bookmark

Share

Key Points

This analysis aims to assess the efficacy and safety of guselkumab in East Asian participants with moderately to severely active Crohn's disease.
Subgroup analysis from phase 3 GALAXI 2 and 3 trials (NCT03466411).
Participants randomized to receive guselkumab 200 mg IV every 4 weeks, 100 mg SC every 8 weeks, 200 mg SC every 4 weeks, ustekinumab, or placebo.
Co-primary endpoints focused on clinical response and remission rates at specified weeks.
Clinical response rates at week 12: 55.6% (100 mg SC q8w) and 51.0% (200 mg SC q4w) versus 3.1% for placebo.
Endoscopic response rates at week 48: 44.4% (100 mg SC q8w) and 39.2% (200 mg SC q4w) versus 0% for placebo.
Adverse event rates remained consistent with the global population.

We only have this paper's title and publication details.

Answers are grounded in this paper and cite their sources.

Shows guselkumab improves outcomes in East Asian participants with Crohn's disease, suggesting effective treatment potential.

No takes yet. Share an insight, caveat, or question.

Nakase et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share